Targeting the PI5P4K Lipid Kinase Family in Cancer Using Covalent Inhibitors.

Autor: Sivakumaren SC; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Shim H; Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY 10065, USA., Zhang T; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Ferguson FM; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Lundquist MR; Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY 10065, USA., Browne CM; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Seo HS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Paddock MN; Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY 10065, USA., Manz TD; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA; Department of Pharmaceutical and Medicinal Chemistry, Saarland University, Saarbruecken, Germany., Jiang B; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Hao MF; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Krishnan P; Department of Medicine, Division of Hematology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA., Wang DG; Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY 10065, USA., Yang TJ; Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY 10065, USA., Kwiatkowski NP; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA; Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA., Ficarro SB; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Cunningham JM; Department of Medicine, Division of Hematology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA., Marto JA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Dhe-Paganon S; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Cantley LC; Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY 10065, USA. Electronic address: lcantley@med.cornell.edu., Gray NS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA. Electronic address: nathanael_gray@dfci.harvard.edu.

Publikováno v: Cell chemical biology [Cell Chem Biol] 2020 May 21; Vol. 27 (5), pp. 525-537.e6. Date of Electronic Publication: 2020 Mar 03.

Publisher Correction: Suppression of insulin feedback enhances the efficacy of PI3K inhibitors.

Autor: Hopkins BD; Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA., Pauli C; Institute of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.; Englander Institute for Precision Medicine, Weill Cornell Medicine-New York Presbyterian Hospital, New York, NY, USA., Du X; Department of Medicine, Division of Hematology and Oncology, Columbia University Medical Center and New York Presbyterian Hospital, New York, NY, USA., Wang DG; Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.; Weill Cornell Medicine/Rockefeller University/Sloan Kettering Tri-Institutional MD-PhD Program, New York, NY, USA., Li X; Weill Cornell Graduate School of Medical Sciences, New York, NY, USA., Wu D; Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA., Amadiume SC; Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA., Goncalves MD; Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.; Division of Endocrinology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA., Hodakoski C; Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA., Lundquist MR; Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA., Bareja R; Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.; Englander Institute for Precision Medicine, Weill Cornell Medicine-New York Presbyterian Hospital, New York, NY, USA.; Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, USA., Ma Y; Department of Medicine, Division of Hematology and Oncology, Columbia University Medical Center and New York Presbyterian Hospital, New York, NY, USA., Harris EM; Department of Medicine, Division of Hematology and Oncology, Columbia University Medical Center and New York Presbyterian Hospital, New York, NY, USA., Sboner A; Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.; Englander Institute for Precision Medicine, Weill Cornell Medicine-New York Presbyterian Hospital, New York, NY, USA.; Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, USA.; Department of Pathology, Weill Cornell Medicine, New York, NY, USA., Beltran H; Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.; Englander Institute for Precision Medicine, Weill Cornell Medicine-New York Presbyterian Hospital, New York, NY, USA.; Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, USA., Rubin MA; Englander Institute for Precision Medicine, Weill Cornell Medicine-New York Presbyterian Hospital, New York, NY, USA.; Department of Biomedical Research and the Center for Precision Medicine, , University of Bern and the Inselspital, Bern, Switzerland., Mukherjee S; Department of Medicine, Division of Hematology and Oncology, Columbia University Medical Center and New York Presbyterian Hospital, New York, NY, USA. sm3252@cumc.columbia.edu., Cantley LC; Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA. lcantley@med.cornell.edu.

Publikováno v: Nature [Nature] 2018 Nov; Vol. 563 (7731), pp. E24.

Phosphatidylinositol-5-Phosphate 4-Kinases Regulate Cellular Lipid Metabolism By Facilitating Autophagy.

Autor: Lundquist MR; Meyer Cancer Center, Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USA., Goncalves MD; Meyer Cancer Center, Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USA., Loughran RM; Sanford Burnham Prebys Medical Discovery Institute, Cancer Metabolism and Signaling Networks Program, La Jolla, CA 92037, USA., Possik E; Goodman Cancer Research Center, McGill University, Montréal, Québec, Canada; Department of Biochemistry, McGill University, Montréal, Québec H3G 1Y6, Canada., Vijayaraghavan T; Goodman Cancer Research Center, McGill University, Montréal, Québec, Canada; Department of Biochemistry, McGill University, Montréal, Québec H3G 1Y6, Canada., Yang A; Division of Genomic Stability and DNA Repair, Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Pauli C; Meyer Cancer Center, Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USA; Englander Institute for Precision Medicine, Weill Cornell Medicine-New York Presbyterian Hospital, New York, NY 10065, USA., Ravi A; Sanford Burnham Prebys Medical Discovery Institute, Cancer Metabolism and Signaling Networks Program, La Jolla, CA 92037, USA., Verma A; Meyer Cancer Center, Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USA; Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY 10065, USA., Yang Z; Meyer Cancer Center, Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USA., Johnson JL; Meyer Cancer Center, Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USA., Wong JCY; Meyer Cancer Center, Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USA., Ma Y; Meyer Cancer Center, Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USA., Hwang KS; Meyer Cancer Center, Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USA., Weinkove D; School of Biological and Biomedical Sciences, Durham University, Durham DH1 3LE, UK., Divecha N; The Inositide Laboratory, Centre for Biological Sciences, Southampton University, Southampton, SO17 1BJ, UK., Asara JM; Department of Medicine, Division of Signal Transduction, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA., Elemento O; Meyer Cancer Center, Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USA; Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY 10065, USA., Rubin MA; Meyer Cancer Center, Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USA; Englander Institute for Precision Medicine, Weill Cornell Medicine-New York Presbyterian Hospital, New York, NY 10065, USA., Kimmelman AC; Perlmutter Cancer Center, Department of Radiation Oncology, NYU Medical School, New York, NY 10016, USA., Pause A; Goodman Cancer Research Center, McGill University, Montréal, Québec, Canada; Department of Biochemistry, McGill University, Montréal, Québec H3G 1Y6, Canada., Cantley LC; Meyer Cancer Center, Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USA. Electronic address: lcantley@med.cornell.edu., Emerling BM; Sanford Burnham Prebys Medical Discovery Institute, Cancer Metabolism and Signaling Networks Program, La Jolla, CA 92037, USA. Electronic address: bemerling@sbpdiscovery.org.

Publikováno v: Molecular cell [Mol Cell] 2018 May 03; Vol. 70 (3), pp. 531-544.e9.

Redox modification of nuclear actin by MICAL-2 regulates SRF signaling.

Autor: Lundquist MR; Department of Pharmacology, Weill Cornell Medical College, Cornell University, New York, NY 10065, USA., Storaska AJ; Department of Pharmacology, University of Michigan, Ann Arbor, MI, 48109, USA., Liu TC; Department of Surgery, Weill Cornell Medical College, Cornell University, New York, NY 10065, USA., Larsen SD; Vahlteich Medicinal Chemistry Core, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA., Evans T; Department of Surgery, Weill Cornell Medical College, Cornell University, New York, NY 10065, USA., Neubig RR; Department of Pharmacology, University of Michigan, Ann Arbor, MI, 48109, USA; Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI 48824, USA., Jaffrey SR; Department of Pharmacology, Weill Cornell Medical College, Cornell University, New York, NY 10065, USA. Electronic address: srj2003@med.cornell.edu.

Publikováno v: Cell [Cell] 2014 Jan 30; Vol. 156 (3), pp. 563-76. Date of Electronic Publication: 2014 Jan 16.